Market open

Insulet/$PODD

14:30

22:10

05:45

13:25

21:00

1D1W1MYTD1Y5YMAX

About Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Ticker

$PODD

Sector

Health Care

Trading on

NASDAQ

Industry

Health Care Equipment & Supplies

Headquarters

Acton, United States

Employees

3,000

Website

www.insulet.com

Insulet Metrics

BasicAdvanced

$19B

46.56 $5.74

1.22 -

Price and volume

Market cap

$19B

Beta

1.22

52-week high

$274.45

52-week low

$160.19

Average daily volume

532K

Financial strength

Current ratio

3.676

Quick ratio

2.525

Long term debt to equity

125.152

Total debt to equity

128.909

Interest coverage (TTM)

8.50%

Management effectiveness

Return on assets (TTM)

7.57%

Return on equity (TTM)

48.79%

Valuation

Price to earnings (TTM)

46.557

Price to revenue (TTM)

9.422

Price to book

16.75

Price to tangible book (TTM)

19.38

Price to free cash flow (TTM)

85.668

Growth

Revenue change (TTM)

27.42%

Earnings per share change (TTM)

232.93%

3-year revenue growth (CAGR)

24.13%

3-year earnings per share growth (CAGR)

135.20%

What the Analysts think about Insulet

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Insulet stock.

Insulet Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Insulet Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Insulet News

AllArticlesVideos

Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe

Business Wire·2 days ago

Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Business Wire·5 days ago

Heavy Interest in Insulet's Insulin Delivery Device

FXEmpire·3 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PODD

$

Capital at risk

Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Insulet stock?

Insulet (PODD) has a market cap of $19B as of January 15, 2025.

What is the P/E ratio for Insulet stock?

The price to earnings (P/E) ratio for Insulet (PODD) stock is 46.56 as of January 15, 2025.

Does Insulet stock pay dividends?

No, Insulet (PODD) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Insulet dividend payment date?

Insulet (PODD) stock does not pay dividends to its shareholders.

What is the beta indicator for Insulet?

Insulet (PODD) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.